Our Services
Medical Information
Helpful Resources
Published on: 9/26/2026
Zofran is the brand name for ondansetron, a prescription medication that blocks serotonin receptors to prevent nausea and vomiting caused by chemotherapy, radiation, or surgery. Generic ondansetron contains the same active ingredient at the same strength and works the same way in the body, though inactive ingredients, tablet coatings, and available forms such as oral film or dissolving tablets can differ. Cost, dosing schedules, and drug interactions are also worth reviewing, and there are several important factors to consider before switching between them. See below to understand more about how the brand and generic versions compare and when to talk with a clinician.
If nausea and vomiting keep returning, the more useful question is what is driving it, since persistent nausea can point to anything from medication side effects and migraine to infection, pregnancy, or a gastrointestinal condition that needs different treatment. Taking a free, instant, online symptom check can help you organize your symptoms, understand possible causes, and decide whether to manage this at home or seek care now.
Last reviewed for medical accuracy: 09/26/2026
Zofran is one of the most commonly prescribed medications to prevent nausea and vomiting. If you’ve ever picked up “Zofran” at a pharmacy, you may have seen a less familiar name on the label: the generic name. Understanding what “zofran generic name” means can help you save money and feel confident that you’re getting the same effective treatment.
The term “generic name” refers to the active ingredient in a medication. In this case, ondansetron is the chemical compound that works to block signals in the body that trigger nausea and vomiting. When you buy a generic version, you’re getting ondansetron, just like the brand-name Zofran.
Yes. The U.S. Food and Drug Administration (FDA) requires that generics meet the same rigorous standards as brand-name drugs for:
The only differences you might notice are in the pill’s color, shape, or inactive ingredients (fillers, dyes, coatings). These variations don’t affect how ondansetron works to prevent nausea.
Ondansetron belongs to a class of medications called 5-HT₃ antagonists. In simple terms, it:
You’ll often see ondansetron prescribed for:
Ondansetron comes in several formulations:
Your healthcare provider will choose the form and dose based on:
Most people tolerate ondansetron well. The most frequently reported side effects include:
These effects are usually mild and often improve as your body adjusts. Staying hydrated and moving gently can help manage constipation or fatigue.
Ondansetron is generally safe, but you should watch for rare reactions such as:
If you experience chest pain, fainting, or a fast/irregular heartbeat, seek immediate medical attention. For any troubling or persistent symptoms, consider doing a free, online symptom check, using the doctor approved Ubie Symptom Checker.
Before taking ondansetron:
Switching to generic ondansetron can lower your out-of-pocket costs significantly. Benefits of the generic include:
Always check with your pharmacy or insurance provider about copay assistance programs or price discounts for generics.
While generic ondansetron is safe for most people, always talk to a healthcare professional if you:
And remember—if you’re unsure, it’s never too late to speak to a doctor. For non-urgent concerns or to double-check symptoms, you might also consider a free, online symptom check, using the doctor approved Ubie Symptom Checker.
This information is based on current guidelines from the U.S. Food and Drug Administration, professional medical literature, and standard clinical practice. Always rely on your healthcare provider to make the best decision for your individual needs.
(References)
* Fauser AA, Duclos B, Chemaissani A, Del Favero A, Cognetti F, Diaz-Rubio E, Cortes-Funes H, Conte PF, Dressler H. Therapeutic equivalence of single oral doses of dolasetron mesilate and multiple doses of ondansetron for the prevention of emesis after moderately emetogenic chemotherapy. European Dolasetron Comparative Study Group. Eur J Cancer. 1996 Aug;32A(9):1523-9. doi: 10.1016/0959-8049(96)00132-3. PMID: 8911112.
* Rojanasthien N, Manorot M, Kumsorn B, Nawoot S, Teekachunhatean S, Sangdee C, Apisariyakul A. Pharmacokinetics and bioavailability studies of generic ondansetron, and the innovator preparation, in healthy Thai male volunteers. J Med Assoc Thai. 1999 Jul;82(7):713-20. PMID: 10511774.
* Rojanasthien N, Manorot M, Kumsorn B. Pharmacokinetics and bioequivalence testing of generic ondansetron preparations in healthy Thai male volunteers. Int J Clin Pharmacol Ther. 1999 Nov;37(11):548-54. PMID: 10584976.
* McNulty R. Are all 5-HT3 receptor antagonists the same? J Natl Compr Canc Netw. 2007 Jan;5(1):35-43. doi: 10.6004/jnccn.2007.0005. PMID: 17239324.
* Cánovas M, Rios J, Domenech G, Cebrecos J, Pelagio P, Canals M, Polonio F, Cabré F. Bioequivalence study of 2 orodispersible formulations of ondansetron 8 mg in healthy volunteers. Arzneimittelforschung. 2012 Feb;62(2):59-62. doi: 10.1055/s-0031-1295488. Epub 2012 Feb 16. PMID: 22344549.
* Onifer DJ, Butler FK Jr, Gross K, Otten EJ, Patton R, Russell RJ, Stockinger Z, Burrell E. Replacement of Promethazine With Ondansetron for Treatment of Opioid- and Trauma-Related Nausea and Vomiting in Tactical Combat Casualty Care. J Spec Oper Med. 2015 Summer;15(2):17-24. doi: 10.55460/23QE-HGO7. PMID: 26125161.
* Claus B, Bauters T, Laureys G. Drug shortages in a pediatric stem cell transplantation ward: Challenges and implications. A 5-year bilan. J Oncol Pharm Pract. 2019 Jun;25(4):841-846. doi: 10.1177/1078155218765627. Epub 2018 Mar 29. PMID: 29592767.
* Rajawat GS, Belubbi T, Nagarsenker MS, Abrahamsson B, Cristofoletti R, Groot DW, Langguth P, Parr A, Polli JE, Mehta M, Shah VP, Tajiri T, Dressman J. Biowaiver Monograph for Immediate-Release Solid Oral Dosage Forms: Ondansetron. J Pharm Sci. 2019 Oct;108(10):3157-3168. doi: 10.1016/j.xphs.2019.05.033. Epub 2019 Jun 8. PMID: 31181225.
* Puri P, Parnami P, Chitkara A, Athwal PSS, Khetrapal S. Antibiomania: A Rare Case of Metronidazole-Induced Mania. Cureus. 2021 Jan 1;13(1):e12414. doi: 10.7759/cureus.12414. Epub 2021 Jan 1. PMID: 33409111; PMCID: PMC7779136.
* Nilsson J, Piovesana V, Turini M, Lezzi C, Eriksson J, Aapro M. Cost-effectiveness analysis of NEPA, a fixed-dose combination of netupitant and palonosetron, for the prevention of highly emetogenic chemotherapy-induced nausea and vomiting: an international perspective. Support Care Cancer. 2022 Nov;30(11):9307-9315. doi: 10.1007/s00520-022-07339-1. Epub 2022 Sep 8. PMID: 36074186; PMCID: PMC9633536.
We would love to help them too.
For First Time Users
We provide a database of explanations from real doctors on a range of medical topics. Get started by exploring our library of questions and topics you want to learn more about.
Was this page helpful?
Purpose and positioning of servicesUbie Doctor's Note is a service for informational purposes. The provision of information by physicians, medical professionals, etc. is not a medical treatment. If medical treatment is required, please consult your doctor or medical institution. We strive to provide reliable and accurate information, but we do not guarantee the completeness of the content. If you find any errors in the information, please contact us.